RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report
Patients with metastatic pancreatic cancer have limited treatment options and a dismal prognosis. While RET fusion is rare (0.6%) in pancreatic cancer, the efficacy of RET-targeted treatment in patients with TRIM33-RET fusion has not been previously reported. Herein, we presented a case of a 68-year...
| Hoofdauteurs: | , , , , |
|---|---|
| Formaat: | Artikel |
| Taal: | English |
| Gepubliceerd in: |
Frontiers Media S.A.
2023-04-01
|
| Reeks: | Frontiers in Oncology |
| Onderwerpen: | |
| Online toegang: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1078076/full |